drugset / Trial / NCT03411980

Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

NCT03411980

Phase 1 Completed 26 enrolled Bayer
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of the study is to evaluate the pharmacokinetics of vilaprisan in subjects with moderate to severe renal impairment compared with matched subjects with normal renal function.

Timeline

Start
2018-02-02
Primary completion
2018-10-10
Completion
2019-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilaprisan Other / unclassified 2 mg Oral

Indications